시장보고서
상품코드
1193134

세계의 월경통 치료 시장 : 유형별, 치료법별, 유통 채널별-기회 분석 및 산업 예측(2021-2031년)

Menstrual Cramps Treatment Market By Type, By Treatment, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 207 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

월경통은 하복부의 강한 경련성 통증입니다.

많은 여성들이 생리 직전부터 생리 중까지 월경통을 경험합니다. 자궁내막증이나 자궁근종 등 질환이 원인이 될 수도 있습니다. 월경통의 증상으로는 하복부나 허리와 허벅지가 아플 수 있습니다. 또한 메스꺼움과 대변의 느슨함, 두통, 현기증 등을 경험하는 여성도 있습니다.

세계의 월경통 치료(Menstrual Cramps Treatment) 시장의 성장은 여성의 월경통 증가에 수반하는 월경통 치료에 대한 수요 증가가 주요 요인입니다. 또한 월경통 치료에 대한 인지도 향상은 월경통 치료 시장의 성장을 더욱 뒷받침합니다. 그러나 월경통 치료에 대한 지식 부족과 메스꺼움, 변비, 구토 등 월경통 치료제의 부작용이 시장 성장을 방해했습니다. 한편, 신흥 시장의 성장 기회와 세계 지출 증가는 시장 참가자들에게 유리한 기회를 제공할 것으로 예상됩니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 개요

  • 시장 정의와 범위
  • 주요 조사 결과
    • 주요 투자 포켓
  • Porter’s Five Forces
  • 주요 기업의 포지셔닝
  • 시장 역학
    • 촉진 요인
    • 억제 요인
    • 기회
  • COVID-19 영향 분석

제4장 월경통 치료 시장 : 유형별

  • 개요
    • 시장 규모 및 예측
  • 원발성 월경통
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 다발성 월경통
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 점유율 분석 : 국가별

제5장 월경통 치료 시장 : 치료별

  • 개요
    • 시장 규모 및 예측
  • 비스테로이드성 항염증제
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 호르몬 요법
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 점유율 분석 : 국가별

제6장 월경통 치료 시장 : 유통 채널별

  • 개요
    • 시장 규모 및 예측
  • 병원 약국
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 약국, 소매 약국
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 온라인 제공자
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 점유율 분석 : 국가별

제7장 월경통 치료 시장 : 지역별

  • 개요
    • 시장 규모 및 예측
  • 북미
    • 주요 동향 및 기회
    • 북미의 시장 규모 및 예측 : 유형별
    • 북미의 시장 규모 및 예측 : 치료법별
    • 북미의 시장 규모 및 예측 : 유통 채널별
    • 북미의 시장 규모 및 예측 : 국가별
      • 미국
      • 캐나다
      • 멕시코
  • 유럽
    • 주요 동향 및 기회
    • 유럽의 시장 규모 및 예측 : 유형별
    • 유럽의 시장 규모 및 예측 : 치료법별
    • 유럽의 시장 규모 및 예측 : 유통 채널별
    • 유럽의 시장 규모 및 예측 : 국가별
      • 독일
      • 프랑스
      • 영국
      • 이탈리아
      • 스페인
      • 기타 유럽 지역
  • 아시아 태평양 지역
    • 주요 동향 및 기회
    • 아시아 태평양 지역의 시장 규모 및 예측 : 유형별
    • 아시아 태평양 지역의 시장 규모 및 예측 : 치료법별
    • 아시아 태평양 지역의 시장 규모 및 예측 : 유통 채널별
    • 아시아 태평양 지역의 시장 규모 및 예측 : 국가별
      • 일본
      • 중국
      • 인도
      • 호주
      • 한국
      • 기타 아시아 태평양 지역
  • LAMEA
    • 주요 동향 및 기회
    • LAMEA의 시장 규모 및 예측 : 유형별
    • LAMEA의 시장 규모 및 예측 : 치료법별
    • LAMEA의 시장 규모 및 예측 : 유통 채널별
    • LAMEA의 시장 규모 및 예측 : 국가별
      • 브라질
      • 사우디 아라비아
      • 남아프리카 공화국
      • 기타 LAMEA 지역

제8장 기업 정세

  • 소개
  • 주요 성공 전략
  • 주요 10개사의 제품 매핑
  • 경쟁 대시보드
  • 경합의 히트 맵
  • 주요 발전

제9장 기업 개요

  • AbbVie Inc.
  • Bayer AG
  • Johnson and Johnson
  • Taj Pharmaceuticals Limited
  • Torrent Pharmaceuticals Ltd.
  • Abbott Laboratories
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
LSH 23.03.13

Menstrual cramps are strong cramping pains in lower abdomen. Many women experience menstrual pains shortly before and throughout their periods. It can be caused by conditions such as endometriosis or uterine fibroids. Symptoms of menstrual cramps include throbbing or cramping pain in the lower abdomen, and pain in lower back and thighs. Some women also experience nausea, loose stools, headache, and dizziness.

The growth of global menstrual cramps treatment market is majorly driven by increase in demand for menstrual cramps treatment, owing to rise in cases of menstrual pain in women. In addition, growing awareness of menstrual cramps treatment further drive growth of the menstrual cramps treatment market. However, lack of knowledge regarding menstrual cramps treatment and side effects of menstrual cramps drugs such as nausea, constipation and vomiting hinders the market growth. Conversely, growth opportunities in emerging markets and surge in expenditure worldwide are anticipated to provide lucrative opportunities to the market players.

The menstrual cramps treatment market is segmented into type, treatment, distribution channel, and region. On the basis of type, the market is categorized into primary dysmenorrhea and secondary dysmenorrhea. On the basis of treatment, the market is segregated into non-steroidal anti-inflammatory drugs and hormonal therapy. On the basis of distribution channel, the market is classified into hospital pharmacies and drug stores & retail pharmacies and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major Key players that operate in the global menstrual cramps treatment market are Abbott Laboratories, AbbVie Inc., Bayer AG, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson Private Limited, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Limited, and Torrent Pharmaceuticals.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the menstrual cramps treatment market analysis from 2021 to 2031 to identify the prevailing menstrual cramps treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the menstrual cramps treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global menstrual cramps treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Primary Dysmenorrhea
  • Secondary Dysmenorrhea

By Treatment

  • Non-steroidal Anti-inflammatory Drugs
  • Hormonal Therapy

By Distribution Channel

  • Hospital Pharmacies
  • Drug stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • AbbVie Inc.
    • Bayer AG
    • Johnson and Johnson
    • Taj Pharmaceuticals Limited
    • Torrent Pharmaceuticals Ltd.
    • Abbott Laboratories
    • Dr. Reddy's Laboratories Ltd.
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Sun Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Primary Dysmenorrhea
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Secondary Dysmenorrhea
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country

CHAPTER 5: MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Non-steroidal Anti-inflammatory Drugs
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 Hormonal Therapy
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country

CHAPTER 6: MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospital Pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market share analysis by country
  • 6.3 Drug stores and Retail Pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market share analysis by country
  • 6.4 Online Providers
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market share analysis by country

CHAPTER 7: MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Type
    • 7.2.3 North America Market size and forecast, by Treatment
    • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Key market trends, growth factors and opportunities
      • 7.2.5.1.2 Market size and forecast, by Type
      • 7.2.5.1.3 Market size and forecast, by Treatment
      • 7.2.5.1.4 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Key market trends, growth factors and opportunities
      • 7.2.5.2.2 Market size and forecast, by Type
      • 7.2.5.2.3 Market size and forecast, by Treatment
      • 7.2.5.2.4 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Key market trends, growth factors and opportunities
      • 7.2.5.3.2 Market size and forecast, by Type
      • 7.2.5.3.3 Market size and forecast, by Treatment
      • 7.2.5.3.4 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Type
    • 7.3.3 Europe Market size and forecast, by Treatment
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Key market trends, growth factors and opportunities
      • 7.3.5.1.2 Market size and forecast, by Type
      • 7.3.5.1.3 Market size and forecast, by Treatment
      • 7.3.5.1.4 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Key market trends, growth factors and opportunities
      • 7.3.5.2.2 Market size and forecast, by Type
      • 7.3.5.2.3 Market size and forecast, by Treatment
      • 7.3.5.2.4 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Key market trends, growth factors and opportunities
      • 7.3.5.3.2 Market size and forecast, by Type
      • 7.3.5.3.3 Market size and forecast, by Treatment
      • 7.3.5.3.4 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Key market trends, growth factors and opportunities
      • 7.3.5.4.2 Market size and forecast, by Type
      • 7.3.5.4.3 Market size and forecast, by Treatment
      • 7.3.5.4.4 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Key market trends, growth factors and opportunities
      • 7.3.5.5.2 Market size and forecast, by Type
      • 7.3.5.5.3 Market size and forecast, by Treatment
      • 7.3.5.5.4 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Key market trends, growth factors and opportunities
      • 7.3.5.6.2 Market size and forecast, by Type
      • 7.3.5.6.3 Market size and forecast, by Treatment
      • 7.3.5.6.4 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Treatment
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Key market trends, growth factors and opportunities
      • 7.4.5.1.2 Market size and forecast, by Type
      • 7.4.5.1.3 Market size and forecast, by Treatment
      • 7.4.5.1.4 Market size and forecast, by Distribution Channel
      • 7.4.5.2 China
      • 7.4.5.2.1 Key market trends, growth factors and opportunities
      • 7.4.5.2.2 Market size and forecast, by Type
      • 7.4.5.2.3 Market size and forecast, by Treatment
      • 7.4.5.2.4 Market size and forecast, by Distribution Channel
      • 7.4.5.3 India
      • 7.4.5.3.1 Key market trends, growth factors and opportunities
      • 7.4.5.3.2 Market size and forecast, by Type
      • 7.4.5.3.3 Market size and forecast, by Treatment
      • 7.4.5.3.4 Market size and forecast, by Distribution Channel
      • 7.4.5.4 Australia
      • 7.4.5.4.1 Key market trends, growth factors and opportunities
      • 7.4.5.4.2 Market size and forecast, by Type
      • 7.4.5.4.3 Market size and forecast, by Treatment
      • 7.4.5.4.4 Market size and forecast, by Distribution Channel
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Key market trends, growth factors and opportunities
      • 7.4.5.5.2 Market size and forecast, by Type
      • 7.4.5.5.3 Market size and forecast, by Treatment
      • 7.4.5.5.4 Market size and forecast, by Distribution Channel
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Key market trends, growth factors and opportunities
      • 7.4.5.6.2 Market size and forecast, by Type
      • 7.4.5.6.3 Market size and forecast, by Treatment
      • 7.4.5.6.4 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Type
    • 7.5.3 LAMEA Market size and forecast, by Treatment
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Key market trends, growth factors and opportunities
      • 7.5.5.1.2 Market size and forecast, by Type
      • 7.5.5.1.3 Market size and forecast, by Treatment
      • 7.5.5.1.4 Market size and forecast, by Distribution Channel
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Key market trends, growth factors and opportunities
      • 7.5.5.2.2 Market size and forecast, by Type
      • 7.5.5.2.3 Market size and forecast, by Treatment
      • 7.5.5.2.4 Market size and forecast, by Distribution Channel
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Key market trends, growth factors and opportunities
      • 7.5.5.3.2 Market size and forecast, by Type
      • 7.5.5.3.3 Market size and forecast, by Treatment
      • 7.5.5.3.4 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Key market trends, growth factors and opportunities
      • 7.5.5.4.2 Market size and forecast, by Type
      • 7.5.5.4.3 Market size and forecast, by Treatment
      • 7.5.5.4.4 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 AbbVie Inc.
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Bayer AG
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Johnson and Johnson
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Taj Pharmaceuticals Limited
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Torrent Pharmaceuticals Ltd.
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Abbott Laboratories
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Dr. Reddy's Laboratories Ltd.
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 GlaxoSmithKline plc
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Pfizer Inc.
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Sun Pharmaceutical Industries Ltd.
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제